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ABBREVIATIONS 
 
DCs Dendritic cells 
DDCs Dermal dendritic cells 
NB-UVB Narrow band ultraviolet B 
PASI Psoriasis area and severity index 
SD Standard deviation 
Teff Effector T cells 
Treg Regulatory T cells 
 
Summary 
Background Psoriasis is a chronic T cell-mediated skin disease with marked social and economic 
burdens. Current treatments are unsatisfactory, with unpredictable remission times and 
incompletely understood modes of action. Recent advances in our understanding of the 
pathogenesis of psoriasis identify the imbalance between CD4+ T effector cells, particularly the T 
helper (Th) 17 subset, and regulatory T cells (Treg) as key to the development of psoriatic lesions, 
and therefore a novel therapeutic target. 
 
Objectives To quantify in patients the effects of three commonly used psoriasis treatment modalities 
on the Th1, Th2, Th17 and Treg subsets, and test whether any change correlates with clinical 
response. 
Methods Using flow cytometry to enumerate Th1, Th2, Th17 and Treg subsets in blood and skin of 
psoriatic patients before and after receiving any of the following treatments; narrow band UVB (NB-
UVB), adalimumab and topical betamethasone/calcipotriol combination (Dovobet®) 
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Results All patients responded clinically to treatments. NB-UVB significantly increased the numbers 
of circulating and skin Treg, while, by contrast, adalimumab reduced Th17 cells in these 
compartments, and Dovobet had dual effects by both increasing Treg and reducing Th17 cells. 
 
Conclusions The differential effects reported here for the above-mentioned treatment modalities 
could be exploited to optimize or design therapeutic strategies to better overcome the inflammatory 
drivers and restore the Th17/Treg balance in psoriasis. 
 
Key words: Psoriasis; Th17/Treg subsets; Dovobet®; NB-UVB; adalimumab 
 
INTRODUCTION 
Psoriasis is a chronic relapsing skin disease that affects 2-4% of the population in western countries.1 
Although not contagious, psoriasis greatly impacts on the patients’ quality of life, and has been 
linked with social stigmatisation, discomfort, and psychological distress.2 Despite the availability of 
many treatments, responses remain unsatisfactory, and the frequent relapses, together with 
absence of long-term control, make psoriasis a challenging condition. This therapeutic inadequacy 
reflects the need for a more complete understanding of the cellular and molecular determinants of 
psoriasis. An important advance has been recognition that the disease is mediated by T cells, and 
that different CD4+ T helper (Th) cell or T regulatory (Treg) subsets can drive or control the 
pathogenic responses. For many years, psoriasis was classified as a Th1 mediated skin disease.3 
However, the recent description of abundant Th17 cells in psoriasis lesions,4 and the evidence of 
impaired Treg function,5 have led to a new model in which the disease is caused by an imbalance 
between inflammatory effector T (Teff) cells, represented by Th17 and to a lesser extent Th1 
subsets, and Treg cells.5 Although skewing a Th17 bias back towards Treg is emerging as a rational 
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therapeutic goal in psoriasis, it is not known how effectively conventional and more recent 
treatments correct this balance, and whether any such restoration correlates with clinical 
improvement. Non-selective treatments such as cyclosporine,6 inhibit both Teff and Treg, leading to 
rebound of psoriasis on stopping therapy. Narrow band UVB (NB-UVB) is a popular and effective 
tool; yet the molecular mechanisms underlying its efficacy are incompletely understood.7 More 
recently, anti TNF-α reagents such as adalimumab have emerged as valuable biologic agents with 
significant anti-inflammatory effects, although, with introduction to regular clinic use, they are 
associated with side effects, loss of efficacy and paradoxical cases of psoriasis.8 Dovobet, containing 
betamethasone and the synthetic vitamin D derivative calcipotriol, is widely used in clinical practice 
owing to its complementary anti-proliferative and anti-inflammatory mechanisms.9 Vitamin D3 
analogues were also found to have beneficial effects in murine models of autoimmune, allergic, and 
inflammatory diseases.10 Overall, we suggest that better understanding of the mechanisms of 
success of these treatments can lead to innovation of new, more targeted, therapeutic strategies 
with fewer side effects. In this study we quantified the effect of NB-UVB, adalimumab and Dovobet® 
on circulating and skin T cells, with particular interest in the critical balance between Th17 and Treg 
cells, and correlated these changes to clinical response measured by psoriasis area and severity 
index (PASI) score. In particular, we wanted to test whether the most effective treatments would 
skew this balance in favour of Treg, which are predicted to be important for immune tolerance and 
prevention of autoimmunity.                                         
PATIENTS AND METHODS 
Patients 
This study was approved by the North of Scotland Research Ethics Committee and MHRA according 
to the Declaration of Helsinki protocols. All participants signed written informed consent. Thirty four 
patients (23 M and 11 F; mean age 50 ± 14.5) were recruited from Aberdeen Royal Infirmary, 
Scotland, UK with moderate to severe psoriasis untreated with topical therapy for 2 weeks or with 
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systemic therapy for 4 weeks. Blood samples, and 6 mm punch biopsies were taken from lesional 
skin at baseline and 6 weeks after treatment with each of: NB-UVB (n = 15), adalimumab (n = 11) and 
Dovobet® (n = 8). Non-lesional 6 mm punches were taken from one group of patients (n = 8) at 
baseline. The number of subjects studied was limited by the restricted inclusion and exclusion 
criteria as we were looking for treatment naïve patient to avoid bias in results. Lesional biopsies 
were taken from the centre of plaques and non lesional samples were taken from the adjacent 
psoriasis free skin. Post treatment samples were collected from cleared psoriasis skin in same site of 
pre-treatment samples. We chose 6 weeks for post treatment samples as data from previous similar 
experiments showed significant immune response to treatment as early as 4-6 weeks. Psoriasis 
patients for whom the decision to treat with NB-UVB was made, were exposed to known amounts of 
NB-UVB three times weekly according to a standard escalating protocol based on minimal erythema 
dose (MED). MED is defined as the dose that caused just perceptible erythema 24 hours after 
irradiation. Standard dose ranges between 0.55 and 3.13 J/cm2. Whole-body UV-B was given in a 
Waldmann 7001 cabinet (Waldmann GmbH, Germany), incorporating twenty-four 100-W Philips TL-
01 fluorescent lamps (311-313 nm). We recruited additional NB-UVB candidates to give 6 mm punch 
skin biopsies at baseline and 2 weeks after treatment. Adalimumab is a preloaded pen device which 
automatically injects the drug by subcutaneous (SC) infusion. It was done by the patient at home 
after initial illustration and training by doctor or the biologic nurse. Dose: 80 mg subcutaneously at 
week 0, 40 mg at week one, and then every other week thereafter. Betamethasone/calcipotriol 
(Dovobet®) is prescribed as a twice daily dose for six weeks to the affected areas. The selection of 
patient to treatment arm was not part of the study and was solely dictated by the clinical need. 
Control samples were provided by psoriasis-free patients who attended the dermatology clinic for 
excision of naevi.  
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Samples 
Skin samples were physically disaggregated ex vivo for 1 minute using 50 μM medicons in the 
Medimachine (BD Biosciences, USA), allowing for collection of viable lymphocytes11 and the cell 
suspension was then used for culture or flowcytometry. PBMC were obtained by density gradient 
centrifugation (Ficoll-Paque; Amersham Biosciences, USA).  
 
Flow cytometric analyses 
Cell suspensions were analysed using BD LSRII research flowcytometry, after staining with 
combinations of the following antibodies and their isotype controls: Anti-CD4-APC-CY7 (BD 
Pharmingen, USA), anti CD25-Alexa Fluor 700 (BD Pharmingen, USA), anti CCR4-PE-CY7 (BD 
Pharmingen, USA), anti CCR6-Alexa Fluor 647 (BioLegend), anti CD127-Alexa Fluor 647 (BD 
Pharmingen, USA), anti FoxP3-Alexa Fluor 488 (BD Pharmingen, USA), anti GATA-3-Alexa Fluor 647 
(BD Pharmingen, USA), and anti Tbet-PE (Santa Cruz). For intracellular staining, cells were fixed and 
permeabilised using the cytofix/Cytoperm kit (BD Biosciences, USA) as per manufacturer’s protocol. 
Data were analysed using FlowJo® version 7.6 (Tree Star Inc., USA). Lymphocyte population was 
selected then identification of pure CD4+ proportion of T cells was gated on isotype control. The cell 
populations were calculated as percentages of CD4+ T cells to the whole lymphocytic count and 
presented as mean  SD. Identification of different T cell subsets and gating is shown in Figure S6, 
S7, S8 and S9. 
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Statistical analysis 
Statistical analyses were carried out using Prism® graphpad 5 for windows; version 5.02, 2008.  Two-
tailed Paired T test was used to compare proportions of cells in lesional versus non-lesional skin, and 
blood of patients.  Mann-Whitney U test was used to compare the proportions of cells between 
blood and skin of patients and healthy controls.  The changes in proportions of T cell subsets with 
treatment were correlated to changes in PASI score using Spearman correlation. The level of 
significance was taken as P ≤ 0.05. 
 
RESULTS 
Clinical response 
To study the clinical and immunological effects of three different therapies, 34 patients with 
moderate to severe psoriasis were recruited and received 6-week treatment regimens of NB-UVB 
(n=15), adalimumab (n=11), or Dovobet® (n=8). All patients responded clinically to treatment with 
mean (±SD) PASI for each treatment group decreased from 5.7 ± 4.3 to 1.5 ± 1.2, 16.03 ± 6.1 to 5.6 ± 
5, and 5.03 ± 5 to 1.7 ± 8, respectively.  
 
The skin and blood of psoriasis patients (n = 8) contain significantly higher proportions of 
Th17 cells and lower proportions of Treg compared to healthy controls (n = 5) 
The proportions of CD4+ Th cells with Th1, Th2, Th17 and Treg phenotypes were compared in 
lesional and non-lesional skin, and in blood, of psoriasis patients at enrolment to the study.  In line 
with reports describing the phenotypes of these subsets, and our own previous studies4, we used 
the characteristic combinations of markers CD4+Tbet+, CD4+GATA-3+, CD4+CCR4+CCR6+IL-23R+ and 
CD4+CD25+FoxP3+CD127lo respectively to identify Th1, Th2, Th17 and Treg cells. The choice of Th17 
markers was based on literature indicating significant expression of the characteristic combination of 
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CCR4+ and CCR6+ on Th17 cells12-14, and CCR6 is critically required for IL-23 induced psoriasis 
lesions15. IL-23 helps in the development of Th17 cells16,17 and the IL-23R is only expressed on 
activated T cells18. RoRγT is the transcription factor for Th17 cells19, and is also expressed by dermal 
γδ T cells15. We did not rely on IL- 17A expression to identify Th17 cell population, because IL-17A 
can be produced by other cells, including γδ T cells, CD8+ memory T cells, eosinophils, neutrophils, 
monocytes and mast cells, contributing to the common pole of IL-17 in psoriasis. 20-23 Due to this 
complex origin and phenotyping of Th17 cells, we chose to combine the characteristic chemokines 
(CCR4+ CCR6+), with IL-23R for purification and identification of Th17 cells population. Examples of 
representative flow cytometric data from the blood and skin of patients and healthy controls are 
illustrated in Figures S1 and S2, and the results are summarized in Figure 1.  The most striking 
findings were that patients’ lesional skin and blood contained both significantly higher proportions 
of Th17 cells compared to respective samples from healthy controls (P = 0.0008, 0.004 respectively), 
and lower proportions of Treg (P = 0.0004, 0.001 respectively). Treg proportions were also 
significantly lower in patients’ non-lesional skin versus healthy donors’ skin (P = 0.007). The highest 
proportions of Th17 cells were found in lesional skin, which were also significantly higher than in 
patients’ non-lesional skin (P = 0.0008). Although Th1 cell numbers were generally higher in blood 
and skin samples from patients versus healthy controls, these increases were not significant, and 
there were also no differences in the proportions of Th2 cells in samples between the groups. Taken 
together, these findings support the view that an imbalance between Th17 and Treg cells 
contributes to psoriasis pathogenesis.                                                                                                                
NB-UVB therapy significantly increased the percentages of circulating and skin regulatory 
T cells (Treg)  
The most marked effect of NB-UVB on the CD4+ subsets of patients was shown on Treg.  Examples of 
flow cytometric analyses are illustrated in Figure S3 a-c.  A summary of NBUVB effects on various T 
cell subsets are shown in Figure 2. In the 15 tested samples, mean circulating and skin Treg 
percentages were significantly increased from 2.96  0.6 to 8.92  1.28 (P = 0.0001), and from 1.47  
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0.8 to 13.6  2.53 (P = 0.0003), respectively after treatment. Th1 cells were also significantly reduced 
from 4.3  0.9 to 1.2  0.6 (P = 0.007) in the blood, and from 6.01  0.9 to 1.5  0.5 (P = 0.02) in the 
skin, while Th2 cells were significantly increased from 0.6  0.4 to 3.05  2.1 in the blood (P = 0.04), 
and from 2.7  0.5 to 4.7  2.7 in the skin (P = 0.01). A reduction in Th17 cells was not statistically 
significant either in the blood or the skin. Strikingly, the change in skin Treg (Δ Treg), but not in the 
other subsets, was positively correlated to clinical improvement assessed by change in PASI score (Δ 
PASI) (Figure S3 d). 
 
Adalimumab therapy significantly reduced Th17 proportions without significant effect on 
Treg 
Patients treated with adalimumab for 6 weeks exhibited a different pattern of shifts in the 
proportions of CD4+ T cell subsets from those seen after NB-UVB treatment, with the main effects 
seen on Th17 cells.  Examples of flow cytometric analyses are illustrated in Figure S4 a-c and a 
summary is displayed in Figure 3.  The greatest effect of adalimumab was on the percentages of 
Th17 cells, which were significantly decreased from 7.1  0.4 to 2.7  0.1 in the blood (P = 0.05), and 
from 21.7  11.6 to 9.5  3.8 in the skin (P = 0.005). The proportions of Th1 and Th2 cells showed 
small non-significant increases, in both the blood and the skin, and there was also no statistically 
significant effect of adalimumab on Treg, with opposing trends for small decreases in blood but small 
increases in skin. The fall in skin Th17 numbers, but none of the other changes, was related to 
clinical improvement, with Δ skin Th17 significantly correlated to Δ PASI. (Figure S3 d).  
 
Treatment with Dovobet ointment significantly affects Th1, Th2, Th17 and Treg  
Dovobet® is a combination of betamethasone dipropionate and active vitamin D (calcipotriol), and 
has a well-established therapeutic role in psoriasis. We showed highly significant, reciprocal systemic 
effects of Dovobet on Th17 and Treg after treatment for 6 weeks.  Examples of flow cytometric 
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analyses are illustrated in Figure S5 a-c, and summarized in Figure 4.  Dovobet® significantly 
increased the percentages of Treg in the circulating (from 3.3 ± 0.6 to 7.3 ± 0.9, P = 0.005) and in the 
skin (from 1.9 ± 1.4 to 8.7 ± 2.3, P = 0.01), and decreased those of Th17 cells (from 4.3 ± 1.1 to 3.4 ± 
0.4, P = 0.003 and from 8.7 ± 0.9 to 5.3 ± 1.8, P = 0.01 respectively). The percentages of Th1 cells 
were also significantly decreased in the skin (P = 0.01), while Th2 cells were increased in the blood (P 
= 0.01). The fall in circulating Th17 numbers, but none of the other changes, was related to clinical 
improvement, since ΔTh17 blood correlated significantly to Δ PASI (Figure S5 d). 
 
DISCUSSION 
The present study of immunological changes associated with three effective treatments for psoriasis 
has, for the first time, revealed differential effects on CD4+ T cell subsets and identified changes that 
correlate with clinical improvement. Patterns of change in the proportions of Teff and Treg subsets 
in the circulation and skin, including those that correlated with clinical improvement, depended on 
treatment type.  The design of the study, comparing patients before and after treatment, allowed 
significant results to be obtained whilst applying stringent inclusion and exclusion criteria, and with 
patients allocated to different treatment arms on the basis of clinical decisions.  The relatively short 
treatment interval focused on initial response rates, which are higher than those expected in longer 
studies that include relapses. Taken together, the results build on the understanding of psoriasis 
pathogenesis as an imbalance between CD4+ subsets by demonstrating that a range of current 
treatments targets the imbalance in different ways, and point to the possibility of improved 
therapies in future. 
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NB-UVB enhanced the number of Treg, reduced Th1 and had no significant effect on Th17, while by 
contrast, adalimumab lowered Th17 cells without noticeable effects on either Th1 or Th17. The 
topical Dovobet® ointment, however, was remarkable for its reciprocal effect in reducing effector 
(Th1 and Th17) subsets whilst increasing the proportion of Treg. Moreover, the increase in UV-
induced Treg, and the Th17 falls caused by adalimumab and Dovobet®, were correlated to 
improvements in PASI score. These results collectively emphasize the importance to therapeutic 
efficacy of restoring a Th17/Treg imbalance in psoriasis and indicate that successful treatment can 
target either one or both sides of the imabalance. Previous reports showed that psoriasis lesional 
Treg are dysfunctional5 or numerically deficient24. Our data showed significant differences in Treg 
numbers between patients and healthy controls, supporting previous findings25,26, and indicating 
that Treg are important to maintain skin immune homeostasis in healthy skin27. The demonstration 
of Th17 enriched in psoriasis lesions compared to normal skin and healthy donor skin strongly 
supports the model of a Th17/Treg immune disturbance in psoriasis and reflects the frequent 
occurrence of skin homing CD4+T lymphocytes (CCR4+CCR6+) in psoriasis plaques, providing more 
evidence that activation and recruitment of Th17 cells is pivotal for psoriasis pathogenesis4. Our 
findings suggest that lesional Treg are numerous but either are dysfunctional or overwhelmed by 
chronic inflammatory microenvironments due to high numbers of Th17 cells and their cytokines. This 
in agreement with data shown by Keijsers et al.28 and Rodriguez et al.29, who reported increased 
percentages and absolute numbers of lesional FoxP3-expressing T cells, as well as, production of IL-
17 and IFN-Y from these cells when compared to non-lesional skin, supporting the concept of T cell 
plasticity30.  The reciprocal increase in Treg and fall in Th17 numbers in response to Dovobet® may 
be an example of a treatment driving subset plasticity in a beneficial direction.  The striking increase 
in CD4+CD25+Foxp3+CD127+lo Treg percentages correlated to clinical response to NB-UVB supports 
the notion that enhanced Treg are key to improve psoriasis through restoration of immune 
tolerance, and the results also raise the possibility that a fall of Th1/2 ratio contributes to beneficial 
effects of NB-UVB. Our use of CD127lo and Foxp3
+ in addition to CD25+ to better define the Treg 
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population confirmed earlier suggestions that restoration of dysfunctional CD4+CD25+T cells could be 
achieved via induction of CD127lo CD4
+CD25+T cells31. Although not statistically significant, NB-UVB 
may have reduced Th17 cells, possibly secondary to Treg stimulation. Notwithstanding such a 
secondary effect NB-UVB emerges as a possible therapeutic tool to enhance Treg without 
compromising the immune defending role of Th17 cells.  The effect of NB-UVB on resident dermal 
dendritic cells (DDCs) to boost Treg has been the focus of a relatively recent study32. Furthermore, 
previous work in our laboratory highlighted a strongly correlated Treg response to serum vitamin D 
level following two weeks of NB-UVB therapy33, but other mediators such as NO may also be 
responsible for the induction by phototherapy of a CD4+CD25+FoxP3- Treg population from 
CD4+CD25- FoxP3- cells34.  We showed for the first time in psoriasis that 6 weeks of treatment with 
adalimumab significantly reduced the percentages of lesional and peripheral blood Th17 cells with a 
strong correlation to clinical response (r2= -0.8, P = 0.03). Other studies have revealed that TNF-α 
antagonists suppressed Th1735 and Th22 signaling36, while others reported enhancement of 
Th1/Th17 cell activation in peripheral blood and inhibition of T cell responses in the skin37. Although 
it has also been reported that anti TNF-α reagents can increase CD4+CD25+FoxP3+ cells in responding 
patients25,26, we did not see such effect. This may be because we used combined markers for Treg 
identification or due to the use of a different anti TNF-α in the other studies. There has been a 
growing interest in the role of vitamin D3 and analogues in the prevention of immune mediated 
diseases. Some studies suggested that vitamin D deficiency is associated with autoimmune 
conditions38, and active vitamin D analogues may prevent such disease by induction of Treg cells33. 
Strikingly, Dovobet® in our study showed significant systemic effects on Teff and Treg. Moreover, the 
fall in circulating Th17 cells was significantly correlated to clinical response (r2 =-0.7, P = 0.04). This 
systemic effect of Dovobet® may be mediated by the response to vitamin D by plasmacytoid DCs39. 
Previous studies showed that vitamin D arrests the maturation of DCs and increases the level of 
regulatory cytokines, IL-10 and TGF-β in murine models of allergic asthma40.  Thus, it is plausible that 
Dovobet improves psoriasis primarily by inducing Treg, and that the effect on Th17 cells is 
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secondary to the release of suppressive cytokines such as TGF-β and IL-10. However, the direct 
suppressive effects of betamethasone on Teff responses are also likely. In conclusion, this study 
identified immunological mechanisms of action of three commonly used psoriasis treatments.  The 
results not only support the model of psoriasis as an immune-mediated disease, in which there is a 
shift in the balance between Treg cells that maintain self-tolerance towards a predominance of 
pathogenic Th17 cells, but the work also has implications for optimizing existing, or developing new, 
treatment regimens. This study reveals that enhancing Treg proportions without necessarily 
compromising Th17 function is an effective treatment approach. The demonstration that existing 
treatments for psoriasis can exert selective effects on Treg and Teff subsets will also encourage a 
search for new strategies that restore tolerance without compromising protection against infectious 
disease.                                                                                               
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FIGURES 
 
 
Figure 1: Proportions of CD4+cell subsets from lesional, non-lesional skin, and blood of psoriasis 
patients at baseline (n = 8), and from skin and blood of healthy controls (n = 5). Flow cytometric 
analyses classified CD4+ T cells as Th1 (CD4+Tbet+), Th2 (CD4+GATA-3+), CD4+CCR4+CCR6+IL-23R+ 
(Th17) and CD4+CD25+FoxP3+CD127lo (Treg).  Note the significant (*) higher proportions of Treg in 
the skin and blood of healthy donors compared to patients (P = 0.0004, 0.001) respectively. The 
proportions of Th17 cells were significantly higher in the blood (P = 0.004) and lesional skin (P = 
0.0008) of patients when compared with the respective samples in the control. Also skin Treg in 
healthy donors were significantly higher when compared to non-lesional Treg of patients (P = 0.007). 
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Figure 2: The effects of NB-UVB treatment of patients with psoriasis on T cell subsets; Th1, Th2, Th17 
and Treg. Summary of flow cytometric data showing in proportions of T cell subsets circulating, and 
in lesional biopsies, from psoriasis patients before and after treatment. Significant changes are 
indicated.  (a) The proportions of Th1 (CD4+T-bet+) cells, (b) The proportions of Th2 (CD4+GATA-3+) 
cells, (c) The proportions of Th17 (CD4+CCR4+CCR6+IL-23R+) cells, (d) The proportions of Treg 
(CD4+CD25+FoxP3+CD127lo) cells. 
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Figure 3: The effects of adalimumab treatment of patients with psoriasis on T cell subsets; Th1, Th2, 
Th17 and Treg. Summary of flow cytometric data showing in proportions of T cell subsets circulating, 
and in lesional biopsies, from psoriasis patients before and after treatment. Significant changes are 
indicated.  (a) The proportions of Th1 (CD4+Tbet+) cells, (b) The proportions of Th2 (CD4+GATA-3+) 
cells, (c) The proportions of Th17 (CD4+CCR4+CCR6+IL-23R+) cells, (d) The proportions of Treg 
(CD4+CD25+FoxP3+CD127lo) cells. 
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Figure 4: The effects of Dovobet® treatment of patients with psoriasis on T cell subsets; Th1, Th2, 
Th17 and Treg. Summary of flow cytometric data showing in proportions of T cell subsets circulating, 
and in lesional biopsies, from psoriasis patients before and after treatment. Significant changes are 
indicated.  (a) The proportions of Th1 (CD4+Tbet+) cells, (b) The proportions of Th2 (CD4+GATA-3+) 
cells, (c) The proportions of Th17 (CD4+CCR4+CCR6+IL-23R+) cells, (d) The proportions of Treg 
(CD4+CD25+FoxP3+CD127lo) cells. 
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